道彤投资
@author-1784793658606
以生命科学为根，向硬科技生长
Articles
Those who act often succeed; those who journey often arrive | Dalton Venture 2023 Year in Review
The Year We Walked Together
My keyword for 2024 is ____, what's yours?
Rather than burning energy worrying in the face of uncertainty, turn that mental clutter into a trail of action — make concrete the things you want to do and the things you can do.
"Inside Listed Companies - LEPU Medical Technology" and "Medical Device Overseas Expansion" Post-Investment Events Successfully Held!
Building a company all the way to an IPO is a long and arduous journey. For healthcare startups, the pursuit of technological breakthroughs runs parallel to challenges across nearly every dimension of the business — corporate strategy, commercial model, capital operations, and day-to-day management.
When the wind is strong, fish fetch a premium — Dalton Venture plays a different game as the catcher.
Only non-consensus views can generate excess returns.
New Order, New Positioning, New Engine | Dalton Venture 2023 Annual Partners Meeting Successfully Held
One gathering closes, another horizon opens. Keep exploring the boundless frontier of innovation!
Mountains, Rivers, and Dreams — Measured in Steps | Dalton Venture 2023 Outing Notes
Running down the hard but right path, staying focused with enduring passion.
Inside the Dalton Family | Mu Liyue of Lanji Medical: From Silicon Valley Back to Xi'an, I Want to Build a Laser Product That Truly Matters to Medicine
Changing the World Through "Medicine-Engineering Integration"
Into the Dalton Family | Exclusive Interview with BioChuang: Pioneering the EDP Technology Platform to Produce High-Performance Chinese "Membranes" --- Walking into the Dalton Family | Exclusive Interview with BioChuang: First-in-Class EDP Technology Platform, Producing High-Performance Chinese "Membranes"
World's First Electrochemical Deposition (EDP) Technology Platform
Inside Dalton Venture's Family of Companies | Boosting Long-Term Survival Rates with a Single Injection: How This Innovative Drug Developer Is Taking on Leukemia
CAR-T cell therapy is seen as a new hope in humanity's fight against cancer.
Into the Dalton Venture Family | Leveraging Two Technology Platforms — Low-Temperature Plasma and Radiofrequency Ablation — Favamed Charts a Platform Strategy
As of today, Fangrun Medical and its subsidiaries have secured 19 NMPA registrations. Its products are now used in over 1,200 hospitals across China, with successful exports to Europe and Southeast Asia, serving more than 100,000 patients annually.